4.6 Article

Arteriovenous Fistula Maturation in Prevalent Hemodialysis Patients in the United States: A National Study

期刊

AMERICAN JOURNAL OF KIDNEY DISEASES
卷 71, 期 6, 页码 793-801

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ajkd.2017.11.020

关键词

-

资金

  1. Amgen
  2. Kyowa Hakko Kirin
  3. AbbVie
  4. Sanofi Renal
  5. Baxter Healthcare
  6. Vifor Fresenius Medical Care Renal Pharma
  7. Keryx Biopharmaceuticals
  8. Merck Sharp Dohme
  9. Proteon Therapeutics
  10. Relypsa
  11. F. Hoffmann-LaRoche
  12. BHC Medical
  13. Janssen
  14. Takeda
  15. Hexal
  16. DGfN
  17. Shire
  18. WiNe Institute
  19. Japanese Society for Peritoneal Dialysis

向作者/读者索取更多资源

Background: Arteriovenous fistulas (AVFs) are the preferred form of hemodialysis vascular access, but maturation failures occur frequently, often resulting in prolonged catheter use. We sought to characterize AVF maturation in a national sample of prevalent hemodialysis patients in the United States. Study Design: Nonconcurrent observational cohort study. Setting & Participants: Prevalent hemodialysis patients having had at least 1 new AVF placed during 2013, as identified using Medicare claims data in the US Renal Data System. Predictors: Demographics, geographic location, dialysis vintage, comorbid conditions. Outcomes: Successful maturation following placement defined by subsequent use identified using monthly CROWNWeb data. Measurements: AVF maturation rates were compared across strata of predictors. Patients were followed up until the earliest evidence of death, AVF maturation, or the end of 2014. Results: In the study period, 45,087 new AVFs were placed in 39,820 prevalent hemodialysis patients. No evidence of use was identified for 36.2% of AVFs. Only 54.7% of AVFs were used within 4 months of placement, with maturation rates varying considerably across end-stage renal disease (ESRD) networks. Older age was associated with lower AVF maturation rates. Female sex, black race, some comorbid conditions (cardiovascular disease, peripheral artery disease, diabetes, needing assistance, or institutionalized status), dialysis vintage longer than 1 year, and catheter or arteriovenous graft use at ESRD incidence were also associated with lower rates of successful AVF maturation. In contrast, hypertension and prior AVF placement at ESRD incidence were associated with higher rates of successful AVF maturation. Limitations: This study relies on administrative data, with monthly recording of access use. Conclusions: We identified numerous associations between AVF maturation and patient-level factors in a recent national sample of US hemodialysis patients. After accounting for these patient factors, we observed substantial differences in AVF maturation across some ESRD networks, indicating a need for additional study of the provider, practice, and regional factors that explain AVF maturation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据